Clinical Trials Directory

Trials / Completed

CompletedNCT03018691

Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Trial to Assess the Safety and Efficacy of 0.3% and 1% OPA-15406 Ointments When Administered for 4 Weeks in Pediatric Patients With Atopic Dermatitis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
73 (actual)
Sponsor
Otsuka Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
2 Years – 14 Years
Healthy volunteers
Not accepted

Summary

To evaluate the safety, efficacy (dose response) and pharmacokinetics of 0.3% and 1% OPA-15406 when applied twice daily for 4 weeks in pediatric patients with atopic dermatitis.

Conditions

Interventions

TypeNameDescription
DRUGOPA-15406
DRUGPlacebos

Timeline

Start date
2017-01-01
Primary completion
2017-06-01
Completion
2017-06-01
First posted
2017-01-12
Last updated
2020-07-23
Results posted
2020-07-23

Locations

4 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT03018691. Inclusion in this directory is not an endorsement.